Financing ·
Senti Biosciences Holdings, Inc. amended its Securities Purchase Agreement to authorize the issuance of a third…
SNTISenti Biosciences Holdings, Inc.
Senti Biosciences Holdings, Inc. amended its Securities Purchase Agreement to authorize the issuance of a third tranche of Senior Secured Convertible Notes valued at $2.0 million to NSG BioInnovation Fund, L.P., satisfying Celadon Partners SPV 35 Limited’s remaining purchase obligation under a July 14, 2026 merger agreement. Simultaneously, the Company received Nasdaq notices for non-compliance with minimum bid price and stockholders’ equity requirements due to a closing bid price below $1.00 and a deficit of $3,401,000 as of June 30, 2026. The Company has until February 23, 2027, to regain bid price compliance and October 11, 2026, to submit a plan for equity compliance, with potential reverse stock splits under consideration. Senti Biosciences operates in the biotechnology industry, developing cell therapies.